Download PDF
Semin Respir Crit Care Med 2010; 31(4): 494-500
DOI: 10.1055/s-0030-1262217
© Thieme Medical Publishers

Sarcoidosis-Associated Pulmonary Hypertension: Assessment and Management

Veronica Palmero1 , 2 , Roxana Sulica1 , 2
  • 1Division of Pulmonary and Critical Care Medicine, Beth Israel Medical Center, New York, New York
  • 2Department of Medicine, Albert Einstein College of Medicine, New York, New York
Further Information

Publication History

Publication Date:
27 July 2010 (online)

    Permissions and Reprints

ABSTRACT

Pulmonary hypertension (PH) is a recognized complication of sarcoidosis, with increased morbidity and poor prognosis. Sarcoidosis-associated pulmonary hypertension (SAPH) is typically seen in advanced cases, with pulmonary fibrosis, destruction and obliteration of the pulmonary vasculature, and chronic hypoxemia. PH can, however, occur in the absence of pulmonary fibrosis, suggesting alternative pathophysiological mechanisms. Diverse processes may coexist in the pathogenesis of SAPH, and there is an overlap with mechanisms of pulmonary arterial hypertension (PAH). This has encouraged the study of PAH-specific therapeutic agents in the treatment of SAPH. In small series, prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors have been shown to improve hemodynamics, functional status, and outcomes. This article reviews the most recent data available in the epidemiology, pathophysiology, diagnosis, and treatment of SAPH.

KEYWORDS

Sarcoidosis - pulmonary hypertension - treatment

REFERENCES

  • 1 Shigemitsu H, Nagai S, Sharma O P. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis.  Curr Opin Pulm Med. 2007;  13 434-438
    PubMedGoogle Scholar
  • 2 Badesch D B, Champion H C, Sanchez M A et al.. Diagnosis and assessment of pulmonary arterial hypertension.  J Am Coll Cardiol. 2009;  54(1, Suppl) S55-S66
    CrossrefPubMedGoogle Scholar
  • 3 Simonneau G, Robbins I M, Beghetti M et al.. Updated clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2009;  54(1, Suppl) S43-S54
    CrossrefPubMedGoogle Scholar
  • 4 Baughman R P, Engel P J, Meyer C A, Barrett A B, Lower E E. Pulmonary hypertension in sarcoidosis.  Sarcoidosis Vasc Diffuse Lung Dis. 2006;  23 108-116
    PubMedGoogle Scholar
  • 5 Handa T, Nagai S, Miki S et al.. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis.  Chest. 2006;  129 1246-1252
    CrossrefPubMedGoogle Scholar
  • 6 Shorr A F, Helman D L, Davies D B, Nathan S D. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.  Eur Respir J. 2005;  25 783-788
    CrossrefPubMedGoogle Scholar
  • 7 Sulica R, Teirstein A S, Kakarla S, Nemani N, Behnegar A, Padilla M L. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension.  Chest. 2005;  128 1483-1489
    CrossrefPubMedGoogle Scholar
  • 8 Nunes H, Humbert M, Capron F et al.. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.  Thorax. 2006;  61 68-74
    CrossrefPubMedGoogle Scholar
  • 9 Takemura T, Matsui Y, Oritsu M et al.. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies.  Virchows Arch A Pathol Anat Histopathol. 1991;  418 361
    CrossrefPubMedGoogle Scholar
  • 10 Rosen Y, Moon S, Huang C T, Gourin A, Lyons H A. Granulomatous pulmonary angiitis in sarcoidosis.  Arch Pathol Lab Med. 1977;  101 170-174
    PubMedGoogle Scholar
  • 11 Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases.  Hum Pathol. 1992;  23 1216-1223
    CrossrefPubMedGoogle Scholar
  • 12 Westcott J L, DeGraff Jr A C. Sarcoidosis, hilar adenopathy, and pulmonary artery narrowing.  Radiology. 1973;  108 585-586
    CrossrefPubMedGoogle Scholar
  • 13 Damuth T E, Bower J S, Cho K, Dantzker D R. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis.  Chest. 1980;  78 888-891
    CrossrefPubMedGoogle Scholar
  • 14 Sperling R T, Creager M A. Nitric oxide and pulmonary hypertension.  Coron Artery Dis. 1999;  10 287-294
    CrossrefPubMedGoogle Scholar
  • 15 Preston I R, Klinger J R, Landzberg M J, Houtchens J, Nelson D, Hill N S. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension.  Chest. 2001;  120 866-872
    CrossrefPubMedGoogle Scholar
  • 16 Giaid A, Yanagisawa M, Langleben D et al.. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.  N Engl J Med. 1993;  328 1732-1739
    CrossrefPubMedGoogle Scholar
  • 17 Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases.  Sarcoidosis. 1995;  12 118-123
    PubMedGoogle Scholar
  • 18 Letizia C, Danese A, Reale M G et al.. Plasma levels of endothelin-1 increase in patients with sarcoidosis and fall after disease remission.  Panminerva Med. 2001;  43 257-261
    PubMedGoogle Scholar
  • 19 Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases.  Lung. 2001;  179 163-174
    CrossrefPubMedGoogle Scholar
  • 20 Baughman R P, Sparkman B K, Lower E E. Six-minute walk test and health status assessment in sarcoidosis.  Chest. 2007;  132 207-213
    CrossrefPubMedGoogle Scholar
  • 21 Arcasoy S M, Christie J D, Ferrari V A et al.. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease.  Am J Respir Crit Care Med. 2003;  167 735-740
    CrossrefPubMedGoogle Scholar
  • 22 Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis.  Eur Respir J. 1990;  3 403-407
    PubMedGoogle Scholar
  • 23 Fisher K A, Serlin D M, Wilson K C, Walter R E, Berman J S, Farber H W. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.  Chest. 2006;  130 1481-1488
    CrossrefPubMedGoogle Scholar
  • 24 Baughman R P, Judson M A, Lower E E et al.. Inhaled iloprost for sarcoidosis associated pulmonary hypertension.  Sarcoidosis Vasc Diffuse Lung Dis. 2009;  26 110
    PubMedGoogle Scholar
  • 25 Milman N, Burton C M, Iversen M, Videbaek R, Jensen C V, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?.  J Heart Lung Transplant. 2008;  27 329-334
    CrossrefPubMedGoogle Scholar
  • 26 Foley R J, Metersky M L. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan.  Respiration. 2008;  75 211-214
    CrossrefPubMedGoogle Scholar
  • 27 Barnett C F, Bonura E J, Nathan S D et al.. Treatment of sarcoidosis-associated pulmonary hypertension: a two-center experience.  Chest. 2009;  135 1455-1461
    CrossrefPubMedGoogle Scholar
  • 28 Macfarlane J T. Prognosis in sarcoidosis.  Br Med J (Clin Res Ed). 1984;  288 1557-1558
    CrossrefPubMedGoogle Scholar
  • 29 Lynch III J P, Kazerooni E A, Gay S E. Pulmonary sarcoidosis.  Clin Chest Med. 1997;  18 755-785
    CrossrefPubMedGoogle Scholar
  • 30 Arcasoy S M, Christie J D, Pochettino A et al.. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation.  Chest. 2001;  120 873-880
    CrossrefPubMedGoogle Scholar
  • 31 Shorr A F, Davies D B, Nathan S D. Outcomes for patients with sarcoidosis awaiting lung transplantation.  Chest. 2002;  122 233-238
    CrossrefPubMedGoogle Scholar
  • 32 Shorr A F, Davies D B, Nathan S D. Predicting mortality in patients with sarcoidosis awaiting lung transplantation.  Chest. 2003;  124 922-928
    CrossrefPubMedGoogle Scholar

Roxana SulicaM.D. 

Division of Pulmonary and Critical Care Medicine, Beth Israel Medical Center

10 Union Square East, Ste. 2A, New York, NY 10003

Email: RSulica@chpnet.org